SG11201501145SA - NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION - Google Patents

NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Info

Publication number
SG11201501145SA
SG11201501145SA SG11201501145SA SG11201501145SA SG11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA SG 11201501145S A SG11201501145S A SG 11201501145SA
Authority
SG
Singapore
Prior art keywords
procnp
biomarker
vascular disorders
pregnancy complication
pregnancy
Prior art date
Application number
SG11201501145SA
Inventor
Eric Arnold Espiner
Timothy Charles Ramsey Prickett
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of SG11201501145SA publication Critical patent/SG11201501145SA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11201501145SA 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION SG11201501145SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261682729P 2012-08-13 2012-08-13
PCT/NZ2013/000142 WO2014027899A1 (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Publications (1)

Publication Number Publication Date
SG11201501145SA true SG11201501145SA (en) 2015-04-29

Family

ID=50101335

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201700872TA SG10201700872TA (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION
SG11201501145SA SG11201501145SA (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201700872TA SG10201700872TA (en) 2012-08-13 2013-08-13 NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Country Status (9)

Country Link
US (1) US10012656B2 (en)
EP (1) EP2883060B1 (en)
JP (1) JP6423788B2 (en)
CN (1) CN104937420B (en)
AU (1) AU2013303302B2 (en)
CA (1) CA2882116A1 (en)
IN (1) IN2015KN00571A (en)
SG (2) SG10201700872TA (en)
WO (1) WO2014027899A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119800A1 (en) 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
EP2883060B1 (en) * 2012-08-13 2018-03-21 Otago Innovation Limited NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US20160106821A1 (en) * 2014-10-20 2016-04-21 Massachusetts Institute Of Technology Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
TWI776812B (en) * 2016-06-02 2022-09-11 荷蘭商菲林公司 Angiotensin-1-receptor antagonists
WO2018216580A1 (en) * 2017-05-22 2018-11-29 東ソー株式会社 Method for providing prognostic prediction information on basis of adrenomedullin concentration fluctuation and reagent therefor
WO2019199865A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in dried physiological samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407580B (en) * 1999-08-20 2001-04-25 Biomedica Gmbh INDICATOR PEPTIDE FOR DIAGNOSIS AND / OR PREDICTION OF CARDIOVASCULAR AND / OR ENDOTHELIAL DISEASES, ANTIBODY COMPOSITION AND IMMUNOASSAY
WO2004099139A1 (en) 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
US7919255B2 (en) * 2003-06-17 2011-04-05 Otago Innovation Limited Assessment of skeletal growth using measurements of NT-CNP peptides
DE10338733A1 (en) 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusion polypeptides and their use for antivascular tumor therapy
WO2008042855A2 (en) 2006-09-29 2008-04-10 The Trustees Of The University Of Pennsylvania Use of ultrasound as an antivascular agent
RU2013102112A (en) * 2010-06-18 2014-07-27 Сезанн С.А.С. MARKERS FOR FORECASTING AND EVALUATING THE RISK OF DEVELOPMENT DUE TO PREGNANCY HYPERTENSION AND PREECLAMPSIA
EP3088416B1 (en) 2011-12-23 2019-02-27 Mayo Foundation for Medical Education and Research Assessing renal structural alterations and outcomes
EP2883060B1 (en) * 2012-08-13 2018-03-21 Otago Innovation Limited NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION

Also Published As

Publication number Publication date
WO2014027899A1 (en) 2014-02-20
JP6423788B2 (en) 2018-11-14
AU2013303302A1 (en) 2015-03-12
US10012656B2 (en) 2018-07-03
EP2883060A1 (en) 2015-06-17
EP2883060B1 (en) 2018-03-21
CA2882116A1 (en) 2014-02-20
CN104937420B (en) 2018-07-03
US20150241451A1 (en) 2015-08-27
AU2013303302B2 (en) 2017-10-12
IN2015KN00571A (en) 2015-07-17
CN104937420A (en) 2015-09-23
EP2883060A4 (en) 2016-06-29
SG10201700872TA (en) 2017-04-27
JP2015526725A (en) 2015-09-10

Similar Documents

Publication Publication Date Title
HK1201452A1 (en) Methods of reducing risk of cardiovascular disease
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
EP2922861A4 (en) Biomarker compositions and methods
EP2895067A4 (en) Evaluation of movement disorders
EP2823306A4 (en) Biomarker compositions and methods
GB201423360D0 (en) Adaptive clustering of locations
SG11201501145SA (en) NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION
ZA201502336B (en) Enzalutamide polymorphic forms and its preparation
GB2499463A9 (en) Reduced sugar syrups and methods of making reducedsugar syrups
EP2852397A4 (en) Huwentoxin-iv variants and methods of use
ZA201405206B (en) Multifunctional structure and method for its manufacture
HK1203464A1 (en) Automatic and vital determination of train length configuration
EP2881113A4 (en) New application of pogostone
GB2502110B (en) Chips and manufacture thereof
GB201214362D0 (en) Conical transition piece
IL237862A0 (en) Methods of reducing scalant formation
PL2903448T3 (en) Hard confectionary and method of manufacture thereof
PL2861242T3 (en) Gluten-related disorders
GB2503216B (en) Continuity of content
IL239426A0 (en) Biomarker methods and compositions
EP2852971A4 (en) Semiconductor constructions and methods of forming semiconductor constructions
ZA201500353B (en) Method of ameliorating clotting pathologies and related materials and methods
GB201416065D0 (en) Catalysts and methods of making and using catalysts
GB201609028D0 (en) Adaptive clustering of locations
PL2931929T3 (en) Alloy for the production of jewels